Introduction

74
The small unilamellar liposomal formulation of amphotericin B (LAmB; 
85
A better understanding of the pharmacological properties of LAmB remains a priority 86 and would enable optimal dosing, particularly for special populations such as infants and 87 children. Dosages ranging from 2.5-10 mg kg -1 per day were studied and each patient was 88 intensively sampled. The individual PK profiles for a sub-population of participants (n=25) 89 were compared at the commencement and end of therapy. volume contracted with time and was described using an exponential decay function. 
159
The 
Results
188
The patient demographics of the study cohort are summarized in and one severe oesophagitis due to C. albicans, and one case of candidaemia caused by C. suggested a paradoxical dose-dependent reduction in exposure at doses >7.5 mg kg -1 , in 267 children higher doses appear to be associated with an increased probability of nonlinearity.
268
The reason for this difference is unclear and warrants further study. primarily due to underlying hemato-oncological diagnoses, and we were not able to further 279 characterise relationships between specific hematological parameters and volume contraction.
280
Other significant data such as plasma HDL concentrations were not quantified in this study.
281
This is an interesting hypothesis that warrants further study in experimental models and/or as order to define target exposure thresholds. 
